Biocept (STU:B00) Total Operating Expense: €18.02 Mil (TTM As of Jun. 2023)


STU:B00 Biocept Inc STU:B00
16 GF Score
Price €6.42
View Full Analysis

What is Biocept Total Operating Expense?

Biocept STU:B00 16 Total Operating Expense is €18.02 Mil as of Jun. 2023. GuruFocus rates STU:B00 with a GF Score™ of 16/100.

Biocept's Total Operating Expense for the three months ended in Jun. 2023 was €3.83 Mil. Biocept's Total Operating Expense for the trailing twelve months (TTM) ended in Jun. 2023 was €18.02 Mil.

Biocept Total Operating Expense Related Terms

Biocept Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Biocept's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biocept Total Operating Expense Chart

Biocept Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Total Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 15.35 15.85 17.75 22.92 27.76

Biocept Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.27 5.44 4.31 4.43 3.83
STU:B00
16GF Score
Biocept Inc STU:B00
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biocept Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €18.02 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of €18.02 Mil mean?
Biocept (STU:B00) has a Total Operating Expense of €18.02 Mil as of Jun. 2023. Total operating expense is the primary recurring expense associated with central operations. View historical data on Biocept and its competitors.
Is Biocept's Total Operating Expense too high?
Biocept's current Total Operating Expense is €18.02 Mil. Overall, Biocept has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Biocept's Total Operating Expense compare to IDTA and DIGP?
Biocept's Total Operating Expense of €18.02 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Medical Diagnostics & Research company?
A good Total Operating Expense depends on the Medical Diagnostics & Research industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Biocept and its competitors. Biocept's current Total Operating Expense is €18.02 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biocept stock overvalued right now?
Biocept (STU:B00) has a current Total Operating Expense of €18.02 Mil. The current Total Operating Expense is €18.02 Mil. Biocept's overall GF Score™ is 16/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Biocept (STU:B00), the current Total Operating Expense is €18.02 Mil as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Biocept Business Description

Address 9955 Mesa Rim Road, San Diego, CA, USA, 92121
Biocept Inc develops and commercializes molecular diagnostic assays that provide physicians with clinically actionable information for treating and monitoring patients diagnosed with a variety of cancers. In addition to its portfolio of blood-based liquid biopsy assays, Biocept has developed the CNSide cerebrospinal fluid assay that detects cancer that has metastasized to the central nervous system. Biocept's patented Target Selector technology captures and quantitatively analyzes CSF tumor cells for tumor-associated molecular markers, using technology first developed for use in blood. It is also leveraging its molecular diagnostic capabilities to offer nationwide COVID-19 RT-PCR testing to support public health efforts during this unprecedented pandemic.
16GF Score

Get the complete analysis for STU:B00

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.42
Price